Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

A Vijenthira, IY Gong, TA Fox, S Booth… - Blood, The Journal …, 2020 - ashpublications.org
Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European …

S Cesaro, P Ljungman, M Mikulska, HH Hirsch… - Leukemia, 2022 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

L Pagano, J Salmanton-García, F Marchesi… - Journal of hematology & …, 2021 - Springer
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

A Sharma, NS Bhatt, A St Martin, MB Abid… - The Lancet …, 2021 - thelancet.com
Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …

COVID-19 and cancer: current challenges and perspectives

Z Bakouny, JE Hawley, TK Choueiri, S Peters, BI Rini… - Cancer cell, 2020 - cell.com
Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This
effect has included the adverse outcomes in patients with cancer who develop COVID-19 …

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active …

F Pimpinelli, F Marchesi, G Piaggio… - Journal of hematology & …, 2021 - Springer
Background Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in
hematological patients; both were evaluated prospectively in 42 patients with multiple …

The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (January 2021)

KE Hanson, AM Caliendo, CA Arias… - Clinical infectious …, 2024 - academic.oup.com
Background Accurate molecular diagnostic tests are necessary for confirming a diagnosis of
coronavirus disease 2019 (COVID-19). Direct detection of severe acute respiratory …

Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence

M Treskova-Schwarzbach, L Haas, S Reda, A Pilic… - BMC medicine, 2021 - Springer
Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …

COVID-19 in patients with hematologic malignancy

P Langerbeins, M Hallek - Blood, The Journal of the American …, 2022 - ashpublications.org
The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …